1865-83-4

Usage

Uses

Used in Fragrance and Flavoring Industry:
7-Methoxy-1,1-diMethyl-3,4-dihydronaphthalen-2(1H)-one is used as a key ingredient in the production of fragrances and flavorings due to its unique aromatic properties. It contributes to the creation of various scents and tastes in a wide range of products, including cosmetics, perfumes, and household products.
Used in Cosmetics:
In the cosmetics industry, 7-Methoxy-1,1-diMethyl-3,4-dihydronaphthalen-2(1H)-one is used as a fragrance component to enhance the sensory experience of the products. Its incorporation into cosmetics adds a pleasant and appealing scent, making the products more attractive to consumers.
Used in Perfumes:
7-Methoxy-1,1-diMethyl-3,4-dihydronaphthalen-2(1H)-one plays a significant role in the perfume industry as a fragrance ingredient. It helps create complex and long-lasting scents by blending with other fragrance compounds, resulting in unique and desirable perfumes.
Used in Household Products:
This chemical compound is also utilized in household products, such as air fresheners and cleaning agents, to provide a pleasant and refreshing scent. Its incorporation into these products improves the overall sensory experience and makes the products more enjoyable to use.
However, it is important to note that 7-Methoxy-1,1-diMethyl-3,4-dihydronaphthalen-2(1H)-one has been identified as a potential allergen and irritant. Therefore, proper safety precautions should be taken when handling 7-Methoxy-1,1-diMethyl-3,4-dihydronaphthalen-2(1H)-one to minimize any adverse effects on health and the environment.

Upstream product

• 4133-34-0 7-methoxyl-2-tetralone 
• 74-88-4 methyl iodide 

Downstream Products

• 1256579-00-6 9-bromo-8-methoxy-6,6-dimethyl-6,11-dihydro-5H-benzo[b]carbazole-3-carbonitrile 
• 52679-89-7 2-Amino-1,1-dimethyl-7-methoxy-1,2,3,4-tetrahydronaphthalin 
• 1256579-01-7 9-bromo-8-methoxy-6,6-dimethyl-6,11-dihydro-5H-benzo[b]carbazole-1-carbonitrile 
• 1256579-06-2 9-bromo-8-hydroxy-6,6-dimethyl-11-oxo-6,11-dihydro-5H-benzo[b]carbazole-3-carbonitrile 
• 1256579-03-9 9-bromo-8-methoxy-6,6-dimethyl-11-oxo-6,11-dihydro-5H-benzo[b]carbazole-3-carbonitrile 
• 1256578-99-0 6-bromo-7-methoxy-1,1-dimethyl-3,4-dihydro-1H-naphthalen-2-one 

Relevant academic research and scientific papers

Synthesis and photocleavage of a new polymerizable [2+2] hetero dimer for phototriggered drug delivery

7-Hydroxy-1,1-dimethylnaphtalenone is introduced as a versatile photocleavable linker system for drug attachment to polymer materials with significantly improved two-photon-absorption efficiency. The synthesis of TBDMS-protected 7-hydroxy-1,1-dimethylnaphtalenone monomer is described, which is the release group attached to the polymer moiety. The cytotoxic 5-fluoro-1-heptanoyluracil was photochemically attached via [2+2] cycloaddition to this release group. The linker-drug conjugate was photochemically polymerized into a HEMA/MMA copolymer. Photo-triggered drug release from the polymer via single-photon-absorption as well as two-photon-absorption in solution were carried out. The detachment of 5-FU from the polymer and its release from the polymer were monitored in the polymer as well as in the aqueous medium and multidose drug release was successfully demonstrated.

IMPROVED PROCESS FOR THE PREPARATION OF 9-ETHYL-6,6-DIMETHYL-8-[4-(MORPHOLIN-4-YL) PIPERIDIN-1-YL]-11-OXO-6,11-DIHYDRO-5H-BENZO[B]CARBAZOLE-3-CARBONITRILE HYDROCHLORIDE

The present invention relates to novel process for the preparation of 9-ethyl-6,6-dimethyl-8-[4-(morpholin-4-yl)piperidin-1-yl]-11-oxo-6,11-dihydro-5H-benzo[b]carbazole-3-carbonitrile hydrochloride compound of formula-1a, represented by the following structural formula: The present invention also provides an improved process for the preparation of tert-butyl-4-(4-ethyl-3-iodophenyl)-4-methyl-3-oxopentanoate having the following structural formula which is useful in the preparation of Alectinib and its pharmaceutical acceptable salts.

4-(2-AMINO-TETRAHYDRONAPHTHALENYL)PYRIMIDINE DERIVATIVE, PREPARATION METHOD THEREFOR, AND PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING CANCER, CONTAINING SAME AS ACTIVE INGREDIENT

The present invention relates to a 4-(2-amino-tetrahydronaphthaleneyl)pyrimidine derivative, a preparation method thereof, and a pharmaceutical composition for the prevention or treatment of cancer comprising the same as an active ingredient. The 4-(2-amino-tetrahydronaphthaleneyl)pyrimidine derivative, the optical isomer thereof, or the pharmaceutically acceptable salt thereof of the present invention is very effective in suppressing anaplastic lymphoma kinase (ALK) activity and as a result it can improve the effectiveness of treatment on cancer cells having anaplastic lymphoma kinase (ALK) fusion proteins such as EML4-ALK and NPM-ALK, so that it can be effectively used as a pharmaceutical composition for preventing or treating cancer.

Four and circular Anaplastic lymphoma kinase inhibitors

The invention belongs to the technical field of medicines, and particularly relates to a four-ring anaplastic lymphoma kinase inhibitor as shown in a general formula (I), or stereisomers, or pharmaceutically acceptable salts, esters or solvates of the inhibitor, wherein A1, A2, A3, M, X, Y, Q, R4, R5, R6, R7 and n are defined in the specification. The invention also relates to a preparation method of these compounds, pharmaceutical preparations and pharmaceutical compositions containing these compounds, and application of the compound or the stereisomers, or the pharmaceutically acceptable salts, esters or solvates of the compound in preparation of medicines for treating and/or preventing ALK-mediated cancer related diseases.

Novel 2,4-diaminopyrimidines bearing tetrahydronaphthalenyl moiety against anaplastic lymphoma kinase (ALK): Synthesis, in vitro, ex vivo, and in vivo efficacy studies

A series of novel 2,4-diaminopyrimidines bearing tetrahydronaphthalenyl moiety were synthesized and evaluated for their anti-anaplastic lymphoma kinase (ALK) activities using enzymatic and cell-based assays. Among the compounds synthesized, compound 17b showed promising pharmacological results in in vitro, ex vivo, and pharmacokinetic studies. An in vivo efficacy study with compound 17b demonstrated highly potent inhibitory activity in H3122 tumor xenograft model mice. A series of kinase assays showed that compound 17b inhibited various kinases including FAK, ACK1, FGFR, RSK1, IGF-1R, among others, thus demonstrating its potential for synergistic anti-tumor activity and development as a multi-targeted non-small cell lung cancer (NSCLC) therapy.

COMPOSITION COMPRISING TETRACYCLIC COMPOUND

A composition which comprises substance represented by Formula (I), [Meanings of the symbols that are included in the formula are given in the specification as definitions] a pharmaceutically acceptable carrier, and a dissolution aid. is useful for improving solubility, oral absorbability and/or absorbability in blood of a poorly water-soluble or water insoluble tetracyclic compounds having an ALK inhibitory activity that are useful as a prophylactic and/or therapeutic agent for cancer, depression, and cognitive function disorder.

TETRACYCLIC COMPOUND

A compound represented by the general Formula (I) below, or a salt or solvate thereof, which is useful as an ALK inhibitor, and is useful for prophylaxis or treatment of a disease accompanied by abnormality in ALK, for example, cancer, cancer metastasis,

Thermal [2 + 2] cycloreversion of a cyclobutane moiety via a biradical reaction

The nature of the Woodward-Hoffmann-forbidden, thermal activated cycloreversion mechanism of cyclobutane has long been the subject of speculation and intense research. We were now able to prove the theoretically postulated biradicalic mechanism directly from radical scavenging reactions and electron paramagnetic resonance (EPR) experiments on [2 + 2] heterodimers of 5-fluoro-1-heptanoyluracil and 7-methoxy-1,1-dimethylnaphthalenon. The dimers show both the "allowed" photochemically as well as the "forbidden" thermally triggered [2 + 2] cycloreversion of the cyclobutane ring. The quantum efficiency of the photochemical cleavage is about 1%. The thermal cycloreversion reaction is independent from solvent and occurs at low activation energies of about 13 kcal/mol, even in the solid state. The radical scavenger and EPR results are further supported by the finding, that the reaction products are solely the educts for the anti-head-to-tail heterodimer. But for the syn-head-to-head heterodimer two additional products are observed, which require a sufficiently stable biradical intermediate to facilitate the required intramolecular rearrangements. Because of the surprisingly high lifetime of the radical species of these heterodimers it was possible to prove the long-discussed biradical mechanism experimentally.

1,1-Dimethylnaphthalenon-dimers as photocleavable linkers with improved two-photon-absorption efficiency and hydrolytic stability

Coumarins are well known for reversible dimer formation with wavelengths greater than 300. nm and dimer cleavage below 300. nm. In a photochemical [2+2]-cycloaddition a cyclobutane ring is formed. Formation as well as cleavage of the cyclobutane ring may be accomplished by a single-photon-absorption as well as by a two-photon-absorption triggered reaction. The coumarin system is of interest for various kinds of applications, ranging from drug delivery for ophthalmic implants to optical data storage. However, the two-photon-absorption coefficient of coumarin dimers is rather low falling in the range of 1. GM in the visible range. We present here a substitute for the coumarin dimer system which not only has an about one order of magnitude higher two-photon-absorption coefficient, but also overcomes several other problems of the coumarin dimer system. Coumarines and in particular coumarine dimers have a very limited solubility in common solvents and are susceptible to hydrolysis of the lactone ring, which leads to an undesired complexity in the photochemical cleavage reaction. The 1,1-dimethylnaphtalenone dimers introduced here show excellent stability, lead only to a single cleavage product, and have a two-photon-absorption coefficient of about 10. GM at 532. nm. These properties make the 1,1-dimethylnaphtalenone dimers a superior substitute over the well-known coumarin dimers in particular in applications where two-photon-absorption induced photocleavage is required.

AMINOTETRALIN COMPOUNDS AS MU OPIOID RECEPTOR ANTAGONISTS

The invention provides aminotetralin compounds of formula (I): wherein R1, R2, R3, R4, R5, R6, R7, n, and m are defined in the specification, or a pharmaceutically-acceptable salt thereof, that are antagonists at the mu opioid receptor. The invention also provides pharmaceutical compositions comprising such compounds, methods of using such compounds to treat conditions associated with mu opioid receptor activity, and processes and intermediates useful for preparing such compounds.